Prediction system and electronic equipment for congenital heart disease and delayed intelligence development

A gene-based prediction method using FKBP8, FAM118A, and SPTB expression data with machine learning models effectively identifies congenital heart disease with intellectual disability, enhancing diagnostic precision and clinical support.

CN119069003APending Publication Date: 2024-12-03DALIAN WOMEN & CHILDREN MEDICAL CENT (GRP)
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202411127026.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a lack of effective prediction methods for congenital heart disease combined with intellectual disability, which hinders timely and personalized prevention and treatment strategies.

Method used

A prediction method utilizing the expression data of target genes FKBP8, FAM118A, and SPTB, combined with machine learning models, to classify samples as congenital heart disease with or without intellectual disability, using mRNA and protein expression data from various sample types.

Benefits of technology

The method achieves high accuracy and specificity in predicting congenital heart disease with intellectual disability, supporting personalized clinical interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119069003A_ABST
    Figure CN119069003A_ABST
Patent Text Reader

Abstract

The invention discloses a system and electronic equipment for predicting congenital heart disease combined with laggard intellectual development, and also provides a method for predicting congenital heart disease combined with laggard intellectual development, the method comprises: obtaining expression data of a target gene of a sample to be detected, the target gene being any one or more of FKBP8, FAM118A and SPTB; performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the to-be-detected sample is a congenital heart disease combined intellectual development laggard sample or not; the method has the advantages of high accuracy, high detection sensitivity and specificity, low cost and the like, is wide in application range, and provides support for clinicians to timely adopt more personalized prevention and treatment schemes for patients with congenital heart diseases and delayed intellectual development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of disease prediction method development, and specifically, relates to a prediction system and electronic device for congenital heart disease combined with intellectual retardation, and more specifically, relates to a prediction method, prediction system, electronic device and computer-readable storage medium for congenital heart disease combined with intellectual retardation. Background Art

[0002] Possible causes of congenital heart disease combined with intellectual disability include chromosomal abnormalities (for example, exposure to radioactive substances, long-term exposure to chemicals, or viral infection during pregnancy may lead to chromosomal abnormalities), intrauterine infection (for example, infection of rubella, coxsackievirus, mumps and other viruses during pregnancy), long-term exposure to harmful substances during pregnancy (for example, long-term exposure to heavy metals, pesticides, benzene and other harmful substances during pregnancy), etc. Congenital heart disease combined with intellectual disability is a type of congenital heart disease (CHD). At present, there is a lack of prediction methods or prediction products in this field that can effectively diagnose or predict congenital heart disease combined with intellectual disability. Summary of the invention

[0003] In view of this, the object of the present invention is to provide a prediction system and electronic equipment for congenital heart disease combined with intellectual disability.

[0004] The present invention also provides a method for predicting congenital heart disease combined with intellectual disability, the method comprising: obtaining expression data of a target gene of a sample to be tested, the target gene being any one or more of FKBP8, FAM118A, and SPTB; performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability.

[0005] The above prediction method provided by the present invention has the advantages of high accuracy, high detection sensitivity and specificity, low cost, etc., and has a wide range of applications, providing support for clinicians to promptly adopt more personalized prevention and treatment plans for patients with congenital heart disease and intellectual disability.

[0006] The present invention adopts the following technical solutions to achieve the above technical objectives:

[0007] A prediction method for congenital heart disease combined with intellectual disability

[0008] The present invention first provides a method for predicting congenital heart disease combined with intellectual disability, the method comprising:

[0009] Acquire expression data of target genes of the sample to be tested, wherein the target genes are any one or more of FKBP8, FAM118A, and SPTB;

[0010] Based on the expression data of the target gene, classification prediction is performed to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0011] If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0012] If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, the classification result of the sample to be tested is obtained as a sample of non-congenital heart disease combined with intellectual disability.

[0013] Further, the classification result is obtained based on the prediction model;

[0014] The method for constructing the prediction model includes: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model.

[0015] Furthermore, the machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

[0016] Further, the target gene expression data includes mRNA expression data of the target gene or protein expression data of the target gene;

[0017] The mRNA expression data is obtained by high-throughput sequencing technology, RT-PCR, qRT-PCR or in situ hybridization technology;

[0018] The protein expression data are obtained by immunoblotting, immunohistochemistry, mass spectrometry or immunoprecipitation.

[0019] Furthermore, the sample to be tested includes a blood sample, a serum sample, a plasma sample, a tissue sample and / or a cell sample.

[0020] A prediction system for congenital heart disease combined with intellectual disability

[0021] The present invention also provides a prediction system for congenital heart disease combined with intellectual disability, the system comprising:

[0022] A data acquisition unit is used to acquire the expression data of the target gene of the sample to be tested, wherein the target gene is any one or more of FKBP8, FAM118A, and SPTB;

[0023] An analysis and prediction unit, used for performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0024] If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0025] If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, a classification result is obtained that the sample to be tested is a sample of non-congenital heart disease combined with intellectual development retardation;

[0026] The classification result is obtained based on the prediction model;

[0027] The method for constructing the prediction model comprises: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model;

[0028] The output result unit is used to output the classification result.

[0029] Furthermore, the machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

[0030] An electronic device

[0031] The present invention also provides an electronic device, comprising a memory and a processor; the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, it is used to execute the steps of the prediction method for congenital heart disease combined with intellectual disability as described above.

[0032] A computer readable storage medium

[0033] The present invention also provides a computer-readable storage medium having a computer program stored thereon, and when the computer program is executed by a processor, the steps of the method for predicting congenital heart disease combined with intellectual disability as described above are implemented.

[0034] New use of reagents for detecting expression levels of target genes FKBP8, FAM118A and / or SPTB

[0035] The present invention also provides the use of a reagent for detecting the expression level of the target gene FKBP8, FAM118A and / or SPTB in a sample to be tested in the preparation of a product for diagnosing congenital heart disease combined with intellectual disability.

[0036] Additional advantages, purposes, and features of the present application will be partially described in the following description, and will become partially apparent to those skilled in the art after studying the following, or may be learned from the practice of the present application. The purposes and other advantages of the present application can be achieved and obtained by the structures specifically pointed out in the specification and the drawings.

[0037] Those skilled in the art will understand that the purposes and advantages that can be achieved by the present application are not limited to the above specific description, and the above and other purposes that can be achieved by the present application will be more clearly understood based on the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0039] Figure 1 A schematic flow chart of a method for predicting congenital heart disease combined with intellectual disability provided by an embodiment of the present invention;

[0040] Figure 2 A schematic diagram of a prediction system for congenital heart disease combined with intellectual disability provided by an embodiment of the present invention;

[0041] Figure 3 A schematic diagram of an electronic device for predicting congenital heart disease combined with intellectual disability provided by an embodiment of the present invention;

[0042] Figure 4 This is an example diagram of the FASTQ data format for read segments;

[0043] Figure 5 is the sequencing quality histogram;

[0044] Figure 6 is the average quality score of the sequence;

[0045] Figure 7 This is a correlation analysis diagram between mRNA samples;

[0046] Figure 8 The volcano plot and heat map (top100) corresponding to the differentially expressed genes;

[0047] Fig. 9 The enrichment results of differentially expressed genes (GO enrichment on the left and KEGG enrichment on the right);

[0048] Fig.10 Figure 2 is the differential expression result of FKBP8, FAM118A and SPTB, where A is a sample from a congenital heart disease patient with normal nutrition and normal intellectual development, and B is a sample from a congenital heart disease patient with normal nutrition and intellectual retardation;

[0049] Fig.11 The results of the diagnostic efficacy validation of FKBP8, FAM118A, and SPTB for predicting congenital heart disease combined with intellectual disability were presented;

[0050] Fig.12 The results of the diagnostic efficacy validation of any two of FKBP8, FAM118A, and SPTB in predicting congenital heart disease with intellectual disability;

[0051] Fig.13 This is the result of validating the diagnostic efficacy of the combination of FKBP8, FAM118A and SPTB in predicting congenital heart disease combined with intellectual disability. DETAILED DESCRIPTION

[0052] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0053] In some of the processes described in the specification and claims of the present invention and the above-mentioned drawings, multiple operations appearing in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this document or may be executed in parallel. The serial numbers of the operations, such as S101, S102, etc., are only used to distinguish different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel.

[0054] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0055] Figure 1 The present invention provides a method for predicting congenital heart disease combined with intellectual disability, and the method comprises the following steps:

[0056] S101: Acquire expression data of a target gene of a sample to be tested, wherein the target gene is any one or more of FKBP8, FAM118A, and SPTB;

[0057] In one embodiment, the sample to be tested is derived from a subject.

[0058] In one embodiment, the subject includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs and cats; laboratory animals, including rodents such as rats, mice and guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish or other non-mammals, etc.

[0059] In one embodiment, the subject is a human.

[0060] In one embodiment, the sample to be tested refers to a composition obtained from or derived from a target subject, which contains cell entities and / or other molecular entities to be characterized and / or identified, for example, based on physical, biochemical, chemical and / or physiological characteristics. The sample can be obtained from the subject's blood and other fluid samples and tissue samples of biological origin, such as biopsy tissue samples or tissue cultures or cells derived therefrom. The source of the tissue sample can be solid tissue, such as from fresh, frozen and / or preserved organ or tissue samples, biopsy tissues or aspirates; blood or any blood component; body fluids; cells from any time of individual pregnancy or development; or plasma.

[0061] In one embodiment, the sample to be tested includes a blood sample, a tissue sample, a blood-derived cell sample, a serum sample, a plasma sample, a lymph fluid sample, a synovial fluid sample, a cell extract sample and / or any combination thereof, derived from a subject.

[0062] In one embodiment, the sample to be tested is a blood sample from a subject.

[0063] In one embodiment, the target gene expression data includes target mRNA expression data or target protein expression data.

[0064] In one embodiment, the mRNA expression data is obtained by high-throughput sequencing technology, RT-PCR, qRT-PCR or in situ hybridization technology. Any method or technology that can be used to detect the mRNA expression level corresponding to a gene can be used in the present invention.

[0065] In one embodiment, the protein expression data is obtained by mass spectrometry, immunoblotting, immunohistochemistry or immunoprecipitation. Any method or technique that can be used to detect the protein expression corresponding to a gene can be used in the present invention.

[0066] In one embodiment, the target gene expression data is the mRNA expression data of the target gene, and the mRNA expression data of the target gene can be obtained by high-throughput sequencing technology. In a specific embodiment of the present invention, the high-throughput sequencing technology is the Illumina high-throughput sequencing platform.

[0067] In one embodiment, the target gene is a combination of any one or more of FKBP8, FAM118A, and SPTB. Specifically, the target gene includes any one of FKBP8, FAM118A, and SPTB, any two combinations of FKBP8, FAM118A, and SPTB, and three combinations of FKBP8, FAM118A, and SPTB.

[0068] S102: performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0069] In one embodiment, the classification result is obtained based on a prediction model;

[0070] The method for constructing the prediction model includes: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model.

[0071] In one embodiment, the machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

[0072] In one embodiment, the target gene expression data includes mRNA expression data of the target gene or protein expression data of the target gene;

[0073] The mRNA expression data is obtained by high-throughput sequencing technology, RT-PCR, qRT-PCR or in situ hybridization technology;

[0074] The protein expression data are obtained by immunoblotting, immunohistochemistry, mass spectrometry or immunoprecipitation.

[0075] In one embodiment, the target gene expression data is the mRNA expression data of the target gene, and the mRNA expression data of the target gene can be obtained by high-throughput sequencing technology. In a specific embodiment of the present invention, the high-throughput sequencing technology is the Illumina high-throughput sequencing platform.

[0076] In one embodiment, the sample to be tested includes a blood sample, a serum sample, a plasma sample, a tissue sample and / or a cell sample.

[0077] In one embodiment, the method uses the following criteria to determine whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability:

[0078] If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0079] If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, the classification result of the sample to be tested is obtained as a sample of non-congenital heart disease combined with intellectual disability.

[0080] In one embodiment, the effectiveness of the constructed prediction model can also be predicted, that is, another data set containing the target gene expression data corresponding to patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development is taken, and the effectiveness of the constructed prediction model is verified in the data set. It is found that the constructed prediction model can be effectively used in the prediction of congenital heart disease combined with intellectual retardation.

[0081] In one embodiment, the inventors collected blood samples from patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development for sequencing analysis to verify the expression of the above target genes and the diagnostic efficacy of the disease of congenital heart disease combined with intellectual disability. The clinical information of the patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development is shown in Table 1 below.

[0082] Table 1 Clinical information of patients with congenital heart disease and intellectual disability and patients with congenital heart disease and normal intellectual development

[0083]

[0084]

[0085] In one embodiment, based on the sequencing by synthesis (SBS) technology, the Illumina high-throughput sequencing platform is used to sequence the cDNA library, which can produce a large number of high-quality reads. These reads or bases produced by the sequencing platform are called raw data. To facilitate the analysis of sequencing data, the raw image data obtained by Illumina sequencing is converted into sequence data, i.e., FASTQ format, through Base Calling to obtain the most original sequencing data file. The FASTQ format file can record the bases of the measured reads and their quality scores. Figure 4 As shown, the FASTQ format is stored in units of sequencing reads, and each read occupies 4 lines, where the first and third lines consist of file identification marks (sequence identifiers) and read names (IDs) (the first line starts with "@" and the third line starts with "+"; the ID in the third line can be omitted, but the "+" cannot be omitted), the second line is the base sequence, and the fourth line is the sequencing quality score of the base at the corresponding position.

[0086] An Illumina sequencer has two flow cells in one run. A flow cell contains eight lanes. One lane contains two columns. Each column contains 60 tiles. Each tile is seeded with a different cluster. The detailed information in the generated sequencing file identification mark (Sequence Identifiers) is shown in Table 2.

[0087] Table 2 Interpretation of sequencing file identification marks

[0088]

[0089] The quality score of the read is represented by different characters, where the ASCII value of each character minus 33 is the corresponding sequencing quality value. Generally, the base quality ranges from 0-40, that is, the corresponding ASCII code is from "!" (0+33) to "I" (40+33). If the sequencing error rate is represented by E and the base quality value of Illunima HiSeq / Miseq is represented by Q, then the following relationship exists: Formula 1: Q = -10log 10 (E) The error rate of sequencing reads increases as sequencing progresses (see Table 3), which is caused by the consumption of chemical reagents during the sequencing process and is a common feature of the Illumina high-throughput sequencing platform.

[0090] Table 3. Concise correspondence between sequencing error rate and sequencing quality value

[0091]

[0092] In one embodiment, the present application performs data volume statistics on the sequence of the original data, and the results are shown in Table 4. In one embodiment, the present application performs quality control on the sequencing data. Since the original sequencing data may contain sequencing adapter sequences, low-quality reads and other types of redundant sequences, this will seriously affect the quality of subsequent assembly. In order to ensure the accuracy of subsequent bioinformatics analysis, the original sequencing data is first filtered to obtain high-quality sequencing data (clean data). Cutadapt can find and delete redundant sequences such as adapters, primers, polyA tails and other types in reads. Cutadapt (version, 3.5, default parameters) is used to clean the sequencing data. In one embodiment, the present application performs statistics on the data after quality control, and MultiQC supports the integration of quality control results, and performs data volume statistics on the sequence after data quality control. In one embodiment, the present application performs data quality assessment after quality control. Illumina sequencing belongs to the second generation sequencing technology, and a single run can generate billions of reads. Such a large amount of data cannot show the quality of each read one by one; using statistical methods, all sequencing reads are quality assessed, which can intuitively reflect the sequencing quality and library construction quality of the sample from a macro perspective. We perform sequencing-related quality assessment on the sequencing data of each sample. The average quality value of each base position in the reads is as follows: Figure 5 The statistics of the average sequence quality score and the number of reads are shown in Figure 6As shown. In one embodiment, the present application performs gene quantification, HISAT2 (version, 2.1.0) aligns the genome, samtools (version, 1.9) sorts and indexes bam files, QualiMap (version, 2.2.2) quality controls bam files, and featureCounts (version, 1.6.4) performs gene quantification. The reference genome version is GRCh38.primary_assembly.genome.fa.

[0093] Table 4 Sequencing data statistics

[0094]

[0095] The correlation of gene expression levels between samples is an important indicator for testing the reliability of the experiment and whether the sample selection is reasonable. Biological repetition is necessary for biological experiments. There are two main purposes for setting up biological repetition: one is to prove that the biological experimental operations involved are not accidental, but repeatable; the other is to ensure that the subsequent differential gene analysis obtains more reliable results. The correlation of gene expression levels between samples is an important indicator for testing the reliability of the experiment and whether the sample selection is reasonable. The closer the correlation coefficient is to 1, the higher the similarity of the expression patterns between samples. If there are biological repetitions in the sample, the correlation coefficient between biological repetitions is usually required to be higher. The Encode plan recommends that the square of the Pearson correlation coefficient (R2) be greater than 0.92 (under ideal sampling and experimental conditions). In a specific embodiment, we require that R2 between biological replicate samples be at least greater than 0.8. The correlation coefficients within and between groups are calculated based on the count values ​​of all genes / transcripts in the sample, and drawn into a heat map, which can intuitively display the sample differences between groups and the sample repetitions within the group. The sample correlation heat map involved in this embodiment is shown in the figure. Figure 7 shown.

[0096] In one embodiment, the present application performs differential expression analysis. In the transcriptome, determining whether the expression level of a gene in different samples is different is one of the core contents of the analysis. After obtaining the gene expression level, the expression data can be statistically analyzed to screen genes with significant differences between different samples. The differential analysis is mainly divided into two steps: (1) First, the original read count is normalized, mainly to correct the sequencing depth. (2) The hypothesis test probability (P-value) is calculated through a statistical model. The differential expression analysis uses DEseq2, and the screening parameters are pvalue<0.05 and |log2foldchange|>1. Using the above standards, 362 differentially expressed genes were screened between patients with congenital heart disease and intellectual development retardation and patients with congenital heart disease and normal intellectual development, of which 145 genes were upregulated and 217 genes were downregulated. The volcano plot and heat map are shown in the figure. Figure 8 shown.

[0097] In one embodiment, the present application further performs functional enrichment analysis on the differentially expressed genes between the above-mentioned patients with congenital heart disease and intellectual disability and patients with congenital heart disease and normal intellectual development, and uses the David database (https: / / david.ncifcrf.gov / tools.jsp) to perform GO functional enrichment and KEGG functional enrichment analysis on the differentially expressed genes. The screening criteria are: pvalue<0.05, and the enrichment results are as follows: Fig. 9 And as shown in Table 5.

[0098] Table 5 KEGG enrichment results

[0099]

[0100]

[0101] In one embodiment, the present application screened and obtained differentially expressed genes between patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development, including FKBP8, FAM118A, and SPTB. It was verified that FKBP8, FAM118A, and SPTB were significantly differentially expressed between patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development (see Fig.10 ).

[0102] In one embodiment, the present application further verifies the diagnostic efficacy of the screened differentially expressed genes FKBP8, FAM118A, and SPTB in predicting congenital heart disease combined with intellectual developmental retardation, and uses the R package "pROC" (version 1.15.0) to perform receiver operating characteristic (ROC) analysis, and calculates the area under the receiver operating characteristic curve (AUC) to evaluate the accuracy of the above-mentioned single differentially expressed gene, any two differentially expressed genes combined, and three differentially expressed genes combined in predicting congenital heart disease combined with intellectual developmental retardation, wherein the range of the AUC value is 0-1. Among them, when judging the diagnostic efficacy of a single differentially expressed gene in predicting congenital heart disease combined with intellectual developmental retardation, the expression level of a single differentially expressed gene is directly used for analysis, and the level corresponding to the point with the largest Youden index is selected as its cutoff value. When judging the diagnostic efficacy of any two differentially expressed genes combined or three differentially expressed genes combined in predicting congenital heart disease combined with intellectual developmental delay, Logistic regression analysis was performed on the expression levels of each differentially expressed gene, and the probability of each patient having congenital heart disease combined with intellectual developmental delay was calculated through the fitted regression curve, and different probability division thresholds were determined. According to the determined probability division thresholds, the accuracy, specificity and sensitivity of any two differentially expressed genes combined or three differentially expressed genes combined in predicting congenital heart disease combined with intellectual developmental delay were calculated.

[0103] Verification results such as Figure 11-13As shown, the results showed that single genes FKBP8, FAM118A, and SPTB all had high diagnostic efficacy for predicting congenital heart disease combined with intellectual disability. Among them, the AUC value corresponding to FKBP8 was 0.786, the sensitivity was 80%, the specificity was 71.4%, and the cutoff value was 22311.000; the AUC value corresponding to FAM118A was 0.829, the sensitivity was 80%, the specificity was 92.9%, and the cutoff value was 715.500; the AUC value corresponding to SPTB was 0.800, the sensitivity was 60%, the specificity was 92.9%, and the cutoff value was 15.000. The combination of any two genes among FKBP8, FAM118A and SPTB also has high diagnostic efficacy for predicting congenital heart disease combined with intellectual disability. Among them, the AUC value corresponding to FKBP8+FAM118A is 0.957, the sensitivity is 80%, the specificity is 100%, and the cutoff value is 0.682; the AUC value corresponding to FKBP8+SPTB is 0.857, the sensitivity is 80%, the specificity is 92.9%, and the cutoff value is 0.441; the AUC value corresponding to FAM118A+SPTB is 0.986, the sensitivity is 100%, the specificity is 92.9%, and the cutoff value is 0.199. The combination of FKBP8, FAM118A and SPTB also has a high diagnostic efficacy for predicting congenital heart disease combined with intellectual developmental retardation. The AUC value corresponding to FKBP8+FAM118A+SPTB is 1.000, the sensitivity is 100%, the specificity is 100%, and the cutoff value is 0.500. The above verification results prove that FKBP8, FAM118A and / or SPTB have a high diagnostic efficacy for predicting congenital heart disease combined with intellectual developmental retardation, which also proves the effectiveness of the prediction method provided in this application (with high diagnostic efficacy, accuracy, sensitivity and specificity), and can be used for the effective prediction of congenital heart disease combined with intellectual developmental retardation.

[0104] S103: If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0105] If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, the classification result of the sample to be tested is obtained as a sample of non-congenital heart disease combined with intellectual disability.

[0106] In one embodiment, the classification result is obtained based on a prediction model, and the method for constructing the prediction model is as described above.

[0107] In one embodiment, as described above, the present application collects blood samples of patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development for sequencing analysis, and obtains the target gene expression data corresponding to the two clinical characteristics of patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development. The clinical information of the patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development is shown in Table 1. The target gene expression data is extracted and input into the machine learning model to construct a prediction model, and a constructed prediction model is obtained.

[0108] In one embodiment, the machine learning model includes the machine learning model as described above.

[0109] In one embodiment, when the construction method of the above-mentioned prediction model is determined, the threshold value is included in the prediction model, that is, when the prediction model is determined, the threshold value is also determined. The prediction model can predict whether the sample to be tested is a classification result of a sample of congenital heart disease combined with intellectual retardation based on the determined threshold value. The specific judgment result based on the prediction model is: if the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold value, and / or the expression level of FAM118A is higher than the threshold value, the classification result of the sample to be tested is obtained as a sample of congenital heart disease combined with intellectual retardation; if the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold value, and / or the expression level of FAM118A is lower than the threshold value, the classification result of the sample to be tested is obtained as a sample of non-congenital heart disease combined with intellectual retardation.

[0110] Figure 2 : is a schematic diagram of a prediction system for congenital heart disease combined with intellectual disability provided by an embodiment of the present invention. Specifically, the prediction system includes:

[0111] A data acquisition unit is used to acquire the expression data of the target gene of the sample to be tested, wherein the target gene is any one or more of FKBP8, FAM118A, and SPTB;

[0112] An analysis and prediction unit, used for performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0113] If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability;

[0114] If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, a classification result is obtained that the sample to be tested is a sample of non-congenital heart disease combined with intellectual development retardation;

[0115] The classification result is obtained based on the prediction model;

[0116] The method for constructing the prediction model comprises: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model;

[0117] The output result unit is used to output the classification result.

[0118] In one embodiment, the target gene expression data includes mRNA expression data of the target gene or protein expression data of the target gene;

[0119] The mRNA expression data is obtained by high-throughput sequencing technology, RT-PCR, qRT-PCR or in situ hybridization technology;

[0120] The protein expression data are obtained by immunoblotting, immunohistochemistry, mass spectrometry or immunoprecipitation.

[0121] In one embodiment, the machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

[0122] In one embodiment, the prediction model can predict the classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability based on the determined threshold.

[0123] Figure 3 It is a schematic diagram of an electronic device for predicting congenital heart disease combined with intellectual retardation provided by an embodiment of the present invention. Specifically, the electronic device includes a memory and a processor; the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, it is used to execute the steps of the method for predicting congenital heart disease combined with intellectual retardation as described above.

[0124] An embodiment of the present invention further provides a computer-readable storage medium. Specifically, the computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the steps of the prediction method for congenital heart disease combined with intellectual disability as described above are implemented.

[0125] The embodiments of the present invention also provide the use of a reagent for detecting the expression level of the target gene FKBP8, FAM118A and / or SPTB in a sample to be tested in the preparation of a product for diagnosing congenital heart disease combined with intellectual disability.

[0126] In one embodiment, the product includes a detection kit, a detection chip or a detection reagent strip.

[0127] In one embodiment, the detection kit, detection chip or detection reagent strip comprises reagents for detecting the expression level of the target gene FKBP8, FAM118A and / or SPTB in a test sample derived from a subject.

[0128] In one embodiment, the reagents include reagents for detecting the mRNA expression level of FKBP8, FAM118A and / or SPTB in the sample to be tested, reagents for detecting the protein expression level of FKBP8, FAM118A and / or SPTB in the sample to be tested, and / or reagents for detecting the number of FKBP8, FAM118A and / or SPTB positive expression cells in the sample to be tested.

[0129] In one embodiment, the reagent for detecting the mRNA expression level of FKBP8, FAM118A and / or SPTB in the test sample includes primers that specifically amplify FKBP8, FAM118A and / or SPTB, and / or probes that specifically recognize FKBP8, FAM118A and / or SPTB.

[0130] In one embodiment, the reagent for detecting the protein expression level of FKBP8, FAM118A and / or SPTB in the sample to be tested includes an antibody that specifically binds to a protein encoded by FKBP8, FAM118A and / or SPTB, a peptide that specifically binds to a protein encoded by FKBP8, FAM118A and / or SPTB, an aptamer that specifically binds to a protein encoded by FKBP8, FAM118A and / or SPTB, a small molecule compound that specifically binds to a protein encoded by FKBP8, FAM118A and / or SPTB, and / or an affinity protein that specifically binds to a protein encoded by FKBP8, FAM118A and / or SPTB.

[0131] In one embodiment, the reagent for detecting the number of FKBP8, FAM118A and / or SPTB positive expression cells in the sample to be tested includes a reagent for detecting the number of FKBP8, FAM118A and / or SPTB positive expression cells by immunohistochemistry.

[0132] In one embodiment, the primer and amplification primer refer to a nucleic acid fragment containing 5-100 nucleotides. Preferably, the primer or amplification primer contains 15-30 nucleotides that can initiate an enzymatic reaction (e.g., an enzymatic amplification reaction). In a specific embodiment of the present invention, the primer refers to a primer that specifically amplifies the genes FKBP8, FAM118A and / or SPTB.

[0133] In one embodiment, the probe refers to a molecule that can bind to a specific sequence or subsequence or other part of another molecule. In a specific embodiment of the present invention, the probe refers to a probe that specifically recognizes FKBP8, FAM118A and / or SPTB. Unless otherwise indicated, a probe generally refers to a polynucleotide probe that can bind to another polynucleotide (often referred to as a target polynucleotide) through complementary base pairing. Depending on the stringency of the hybridization conditions, the probe can bind to a target polynucleotide that lacks complete sequence complementarity with the probe. Hybridization methods include, but are not limited to, solution phase, solid phase, mixed phase or in situ hybridization assays. Exemplary probes in the present invention include gene-specific DNA oligonucleotide probes, such as microarray probes fixed on microarray substrates, quantitative nuclease protection test probes, probes connected to molecular barcodes, and probes fixed on beads.

[0134] In one embodiment, the detection kit includes an RT-PCR detection kit, an ELISA detection kit, a protein chip detection kit, a rapid detection kit, a DNA chip detection kit, an immunohistochemistry detection kit, or an MRM (multiple reaction monitoring) detection kit.

[0135] In one embodiment, the detection kit may further include elements necessary for reverse transcription polymerase chain reaction. The RT-PCR detection kit includes a pair of primers specific for genes encoding marker proteins. Each primer is a nucleotide with a nucleic acid sequence specific for the gene, and its length may be about 7 to 50bp, more particularly about 10-39bp. In addition, the kit may further include primers specific for the nucleic acid sequence of the control gene; preferably, the RT-PCR detection kit may also include test tubes or suitable vessels, reaction buffers (different pH values ​​and magnesium concentrations), deoxynucleotides (dNTPs), enzymes (such as Taq polymerase and reverse transcriptase), deoxyribonuclease inhibitors, ribonuclease inhibitors, DEPC-water, and sterile water.

[0136] In one embodiment, the detection kit may include elements necessary for operating a DNA chip. The DNA chip kit may include substrates bound to genes or cDNA or oligonucleotides equivalent to fragments thereof, and reagents, agents and enzymes for constructing fluorescently labeled probes. In addition, the substrate may include control genes or cDNA or oligonucleotides equivalent to fragments thereof.

[0137] In one embodiment, the detection kit disclosed in the present invention may include elements necessary for performing ELISA. The ELISA detection kit may include antibodies specific for proteins (proteins encoded by FKBP8, FAM118A and / or SPTB described in the present invention). The antibody has high selectivity and affinity for marker proteins, has no cross-reactivity with other proteins, and may be a monoclonal antibody, a polyclonal antibody or a recombinant antibody. In addition, the ELISA detection kit may include antibodies specific for control proteins. In addition, the ELISA detection kit may further include reagents capable of detecting the bound antibody, for example, a labeled second antibody, a chromophore, an enzyme (for example, conjugated to an antibody), and a substrate thereof or a substance capable of binding the antibody.

[0138] In one embodiment, the detection chip is also referred to as a biochip or array, which refers to a solid support comprising a connected nucleic acid or peptide probe. The array generally comprises a plurality of different nucleic acid or peptide probes connected to the substrate surface according to different known positions. These arrays, also referred to as microarrays, can generally be produced using mechanical synthesis methods or light-guided synthesis methods, which incorporate a combination of photolithography and solid phase synthesis methods. The array may comprise a flat surface, or may be a nucleic acid or peptide on a bead, gel, polymer surface, fiber such as an optical fiber, glass or any other suitable substrate. The array may be packaged in a certain manner, thereby allowing for the diagnosis of a fully functional device or other manipulations. A microarray is an orderly arrangement of hybridization array elements on a substrate, such as polynucleotide probes (e.g., oligonucleotides) or binding agents (e.g., antibodies). The substrate may be a solid substrate, for example, a glass or silica slide, a bead, a fiber optic adhesive, or a semi-solid substrate, such as a nitrocellulose membrane. The nucleotide sequence may be DNA, RNA, or any arrangement thereof.

[0139] In one embodiment, the detection chip includes a gene chip and a protein chip; the gene chip includes a solid phase carrier; and oligonucleotide probes fixed in order on the solid phase carrier, and the oligonucleotide probes specifically correspond to part or all of the sequences shown in FKBP8, FAM118A and / or SPTB. The protein chip includes a solid phase carrier, and specific antibodies or ligands for proteins encoded by FKBP8, FAM118A and / or SPTB fixed on the solid phase carrier.

[0140] The validation results of this validation example show that assigning intrinsic weights to indications can moderately improve the performance of the method relative to the default setting.

[0141] Those skilled in the art can clearly understand that, for the convenience and brevity of description, the specific working processes of the systems, devices and units described above can refer to the corresponding processes in the aforementioned method embodiments and will not be repeated here.

[0142] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.

[0143] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0144] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.

[0145] A person of ordinary skill in the art can understand that all or part of the steps in the various methods of the above embodiments can be completed by instructing related hardware through a program, and the program can be stored in a computer-readable storage medium, and the storage medium may include: a read-only memory (ROM), a random access memory (RAM), a disk or an optical disk, etc.

[0146] A person skilled in the art can understand that all or part of the steps in the above-mentioned embodiment method can be completed by instructing related hardware through a program, and the program can be stored in a computer-readable storage medium. The above-mentioned storage medium can be a read-only memory, a disk or an optical disk, etc.

[0147] The above is a detailed introduction to a computer device provided by the present invention. For a person skilled in the art, according to the concept of the embodiments of the present invention, there may be changes in the specific implementation method and application scope. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A prediction method for congenital heart disease combined with intellectual disability. It is characterized in that The method comprises: Acquire expression data of target genes of the sample to be tested, wherein the target genes are any one or more of FKBP8, FAM118A, and SPTB; Based on the expression data of the target gene, classification prediction is performed to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability; If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability; If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, the classification result of the sample to be tested is obtained as a sample of non-congenital heart disease combined with intellectual disability.

2. The method for predicting congenital heart disease combined with intellectual disability according to claim 1, It is characterized in that The classification result is obtained based on the prediction model; The method for constructing the prediction model includes: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual disability and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model.

3. The method for predicting congenital heart disease combined with intellectual disability according to claim 2, It is characterized in that The machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

4. The method for predicting congenital heart disease combined with intellectual disability according to claim 1, It is characterized in that The target gene expression data includes mRNA expression data of the target gene or protein expression data of the target gene; The mRNA expression data is obtained by high-throughput sequencing technology, RT-PCR, qRT-PCR or in situ hybridization technology; The protein expression data are obtained by immunoblotting, immunohistochemistry, mass spectrometry or immunoprecipitation.

5. The method for predicting congenital heart disease combined with intellectual disability according to claim 1, It is characterized in that The sample to be tested includes a blood sample, a serum sample, a plasma sample, a tissue sample and / or a cell sample.

6. A prediction system for congenital heart disease combined with intellectual disability. It is characterized in that The system comprises: A data acquisition unit is used to acquire the expression data of the target gene of the sample to be tested, wherein the target gene is any one or more of FKBP8, FAM118A, and SPTB; An analysis and prediction unit, used for performing classification prediction based on the expression data of the target gene to obtain a classification result of whether the sample to be tested is a sample of congenital heart disease combined with intellectual disability; If the expression level of any one or more of the target genes FKBP8 and SPTB is lower than the threshold, and / or the expression level of FAM118A is higher than the threshold, a classification result is obtained that the sample to be tested is a sample of congenital heart disease combined with intellectual disability; If the expression level of any one or more of the target genes FKBP8 and SPTB is higher than the threshold, and / or the expression level of FAM118A is lower than the threshold, a classification result is obtained that the sample to be tested is a sample of non-congenital heart disease combined with intellectual development retardation; The classification result is obtained based on the prediction model; The method for constructing the prediction model comprises: obtaining the target gene expression data of the training set samples and the clinical characteristics corresponding to the samples, the clinical characteristics including patients with congenital heart disease combined with intellectual retardation and patients with congenital heart disease combined with normal intellectual development, extracting the target gene expression data in the training set and inputting it into a machine learning model to construct a prediction model, thereby obtaining a constructed prediction model; The output result unit is used to output the classification result.

7. The prediction system for congenital heart disease combined with intellectual disability according to claim 6, It is characterized in that The machine learning model includes a linear regression model, a logistic regression model, a random forest model, a Lasso regression model, a neural network model, a decision tree model, a perceptron model, a support vector machine model and / or a naive Bayes model.

8. An electronic device, It is characterized in that The electronic device includes a memory and a processor; the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, it is used to execute the steps of the prediction method for congenital heart disease combined with intellectual disability as described in any one of claims 1-5.

9. A computer-readable storage medium, It is characterized in that The computer-readable storage medium stores a computer program, which, when executed by a processor, implements the steps of the method for predicting congenital heart disease combined with intellectual disability as described in any one of claims 1 to 5.

10. Use of a reagent for detecting the expression level of the target gene FKBP8, FAM118A and / or SPTB in a test sample in the preparation of a product for diagnosing congenital heart disease combined with intellectual disability.

Citation Information

Cited By

  • Prediction method and system for congenital heart disease combined with backward intelligence development, electronic equipment and storage medium

    CN119068973A

  • A prediction method, system, electronic device and storage medium for congenital heart disease combined with intellectual disability

    CN119068973B

  • Gene feature-based development dynamic expression mode prediction method, model, system and database structure

    CN120636531A

  • Gene signature-based developmental dynamic expression pattern prediction method, model, system and database structure

    CN120636531B